Finally, we analyzed the immune cell landscape and transcriptional characteristics between the high- and low-inflammatory signature groups and identified BRPF1, which is related to the proliferation of glioma cells, as a potential drug target. This evidence concerns the gene BRPF1 and central nervous system cancer.